Novel therapy helps ease pain and suffering for sickle cell patients

September 25, 2012

Chronic, debilitating pain and potential organ failure are what approximately 100,000 sickle cell patients in the United States live with each day. Yutaka Niihara, M.D., M.P.H. - lead investigator at The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) and co-founder of Emmaus Medical, Inc., an LA BioMed spin-off company - is developing a low-cost, noninvasive treatment that helps provide relief for patients suffering from the debilitating effects of sickle cell disease.

Dr. Niihara and his team of investigators discovered that L-glutamine – which is the most common free-form amino acid in the body – can help alleviate many of the painful symptoms associated with sickle cell when used in powder form and added to liquid.

Sickle cell is an inherited disease that causes red blood cells to become oxidized, sticky, and crescent or sickle-shaped instead of smooth, pliable, and round. It can lead to anemia, , chronic and , and a host of other problems. L-glutamine, in its powder form, helps to reduce the oxidation of .

Dr. Niihara first began seeking for sickle cell nearly 20 years ago, after years of seeing patients suffer from this debilitating disease. He was encouraged by Dr. Charles Zerez, an LA BioMed investigator in the 1980s and 1990s, to pursue glutamine research. Of the approximately 80 medications for sickle cell that have entered into clinical trials, this therapy is one of only three experimental treatments to reach Phase III trials, which are usually the last trials conducted before the approves a treatment to be made widely available to the patient population.

"As a physician, I have seen firsthand the suffered by patients with sickle cell disease," said Dr. Niihara. "We are pleased to have reached this stage in our development of this potential treatment, and hope to bring relief to the millions of people suffering from this disorder."

According to the Centers for Disease Control (CDC), there are approximately 100,000 people in the United States living with sickle cell disease, and approximately 3 million people carrying the sickle cell trait. With Dr. Niihara's treatment in clinical trials, this should come as a welcome relief to millions of people worldwide, as other treatment options such as pain medication, hydration, or bone marrow transplants are either not well tolerated, are too costly, or have limited availability.

"We are excited about the potential development of a novel treatment for the millions of people who suffer from the effects of sickle cell disease," said David I. Meyer, Ph.D., president and CEO of LA BioMed. "The achievements of Dr. Niihara and his team of researchers demonstrate the pioneering spirit that has kept LA BioMed at the forefront of medical discoveries that have helped transform the lives of so many."

Dr. Niihara's L-glutamine treatment recently received an Orphan Medicinal Product designation from the European Commission (EC). This designation follows a recommendation announced in May from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products. The therapy currently has orphan drug designation and "fast track" status in the United States, which is a process designed to facilitate the development and expedite the review of drugs to treat serious diseases and fill an unmet medical need.

Explore further: Researchers reveal potential treatment for sickle cell disease

Related Stories

Researchers reveal potential treatment for sickle cell disease

November 2, 2011
A University of Michigan Health System laboratory study reveals a key trigger for producing normal red blood cells that could lead to a new treatment for those with sickle cell disease.

Sickle cell trait is not risk factor for kidney disease

September 14, 2011
Researchers at Wake Forest Baptist Medical Center report that sickle cell trait is not a risk factor for the development of severe kidney disease in African-Americans. This study, published in the August online issue of Kidney ...

Recommended for you

Zika virus stifles pregnant women's weakened immune system to harm baby, study finds

August 21, 2017
The Zika virus, linked to congenital birth defects and miscarriages, suppresses a pregnant woman's immune system, enabling the virus to spread and increasing the chances an unborn baby will be harmed, a Keck School of Medicine ...

Fatty liver can cause damage to other organs via crosstalk

August 21, 2017
Nonalcoholic fatty liver disease is increasingly common. Approximately every third adult in industrialized countries has a morbidly fatty liver. This not only increases the risk of chronic liver diseases such as liver cirrhosis ...

Faulty gene linked to obesity in adults

August 18, 2017
Groundbreaking new research linking obesity and metabolic dysfunction to a problem in the energy generators in cells has been published by researchers from the Harry Perkins Institute of Medical Research and The University ...

Two lung diseases killed 3.6 million in 2015: study

August 17, 2017
The two most common chronic lung diseases claimed 3.6 million lives worldwide in 2015, according to a tally published Thursday in The Lancet Respiratory Medicine.

New test differentiates between Lyme disease, similar illness

August 16, 2017
Lyme disease is the most commonly reported vector-borne illness in the United States. But it can be confused with similar conditions, including Southern Tick-Associated Rash Illness. A team of researchers led by Colorado ...

Addressing superbug resistance with phage therapy

August 16, 2017
International research involving a Monash biologist shows that bacteriophage therapy – a process whereby bacterial viruses attack and destroy specific strains of bacteria - can be used successfully to treat systemic, multidrug ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.